(NASDAQ: MBX) Mbx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.53%.
Mbx Biosciences's earnings in 2026 is -$80,495,000.On average, 11 Wall Street analysts forecast MBX's earnings for 2026 to be -$144,455,196, with the lowest MBX earnings forecast at -$201,539,492, and the highest MBX earnings forecast at -$123,526,233. On average, 11 Wall Street analysts forecast MBX's earnings for 2027 to be -$179,887,602, with the lowest MBX earnings forecast at -$220,991,170, and the highest MBX earnings forecast at -$132,484,242.
In 2028, MBX is forecast to generate -$153,920,601 in earnings, with the lowest earnings forecast at -$210,780,386 and the highest earnings forecast at -$90,994,515.